- In a cash-and-stock deal valuing Allergan (AGN +15.3%) at $152.88/share, Canadian firm Valeant Pharmaceuticals (VRX +5.2%) offers $48.30 in cash and 0.83 shares of its common stock in an unsolicited bid for the Botox maker.
- VRX believes is can wring out at least $2.7B in annual cost savings with the merger but some analysts believe too-aggressive cost cutting could damage AGN's business.
- Traders expect VRX to sweeten its offer, though. Shares currently exchange hands at $164.
From other sites
at CNBC.com (Feb 18, 2015)
at CNBC.com (Feb 10, 2015)
at CNBC.com (Jan 26, 2015)
at CNBC.com (Jan 14, 2015)
at CNBC.com (Jan 13, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs